The Cost-Effectiveness of Herpes Simplex Virus-2 Suppressive Therapy With Daily Aciclovir for Delaying HIV Disease Progression Among HIV-1-Infected Women in South Africa
Peter Vickerman, Angela Devine, Anna M Foss, Sinead Delany-Moretlwe, Philippe Mayaud, Gesine Meyer-Rath
SEXUALLY TRANSMITTED DISEASES | LIPPINCOTT WILLIAMS & WILKINS | Published : 2011
BACKGROUND: The Partners in Prevention HSV/HIV transmission trial (Partners HSV/HIV Transmission Study) showed that herpes simplex virus-2 (HSV-2) suppressive therapy with daily aciclovir could decrease HIV disease progression amongst HIV-1/HSV-2 coinfected individuals. The cost-effectiveness of daily aciclovir for delaying HIV-1 disease progression in women not eligible for antiretroviral therapy (ART) is estimated. METHODS: Resource use/cost data for delivering daily aciclovir at a primary health care HIV clinic were collected in Johannesburg. Effectiveness estimates were obtained from the Partners HSV/HIV Transmission Study trial and epidemiologic data from South Africa. A Markov model si..View full abstract
Supported by UK Department for International Development (DFID)-funded Research Programme Consortium for Research and Capacity Building in Sexual and Reproductive Health and HIV in Developing Countries at the London School of Hygiene and Tropical Medicine. Angela Devine also received a travel grant from the London School of Hygiene and Tropical Medicine. The views expressed are those of the authors and cannot be taken to reflect the official opinions of DFID or the London School of Hygiene and Tropical Medicine.